A new study from the Alzheimer Society of Canada is ringing alarm bells about the increasing number of people dealing with dementia. Called "The Landmark Study: The Many Faces of Dementia in Canada," ...

CNW/ - Today, after more than 35 years of commitment to advancing Alzheimer's research, Lilly Canada announced Health ...

Over the weekend of May 30-31, more than 150 communities across Canada will lace up their shoes for the annual IG Wealth ...

Health Canada has approved Eli Lilly’s donanemab (Kisunla™) for people with mild cognitive impairment or early-stage Alzheimer’s, making it the country’s second disease-modifying treatment. Clinical ...

New treatment approved: Health Canada has authorized Kisunla for adults in early Alzheimer’s stages, marking the second disease-slowing drug available in Canada. Who can get it: The drug is limited to ...

Cochrane reviews aim to analyse and draw conclusions about a particular health-related question. These reviews consider all the high-quality research on a topic and are often used by healthcare ...

One-third of people older than 85 in the United States are estimated to live with Alzheimer’s disease today, according to the National Institute on Aging. The condition’s characteristic long, slow ...

Last week’s report by the Cochrane Collaboration, which concluded breakthrough Alzheimer’s drugs are unlikely to benefit people living with the disease, has attracted widespread debate and some ...